% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koerber:154800,
      author       = {S. A. Koerber and K. Sprute and C. Kratochwil and E. Winter
                      and M. F. Haefner and S. Katayama and I. Schlampp and K.
                      Herfarth and K. Kopka$^*$ and A. Afshar-Oromieh and S.
                      Zschaebitz and T. Holland-Letz$^*$ and P. L. Choyke and D.
                      Jaeger and M. Hohenfellner and U. Haberkorn$^*$ and J.
                      Debus$^*$ and F. Giesel$^*$},
      title        = {{C}linical outcome of {PSMA}-guided radiotherapy for
                      patients with oligorecurrent prostate cancer.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {48},
      number       = {1},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2020-01038},
      pages        = {143-151},
      year         = {2021},
      note         = {2021 Jan;48(1):143-151},
      abstract     = {First-line treatment of patients with recurrent, metastatic
                      prostate cancer involves hormone therapy with or without
                      additional systemic therapies. Prostate-specific membrane
                      antigen (PSMA) positron emission tomography (PET)/computed
                      tomography (CT) allows the detection of oligometastatic
                      disease that may be amenable to image-guided radiotherapy.
                      The current study classifies the type and localization of
                      metastases and the clinical outcome of PSMA-PET/CT-guided
                      radiotherapy to selected metastases.Between 2011 and 2019,
                      86 patients with recurrent, oligometastatic prostate
                      carcinoma were identified by PSMA-PET/CT and were treated
                      with image-guided radiotherapy of their metastases. Sites of
                      relapse were characterized, and the primary endpoint overall
                      survival (OS), biochemical progression-free survival (bPFS),
                      and androgen deprivation therapy (ADT)-free survival were
                      tabulated.In total, $37\%$ of the metastases were bone
                      metastases, $48\%$ were pelvic nodal metastases, and $15\%$
                      were nodal metastases outside of the pelvis. After
                      PSMA-guided radiotherapy, a biochemical response was
                      detected in $83\%$ of the cohort. A statistically
                      significant decrease in the standard uptake value (SUV) was
                      seen in irradiated metastases. After a median follow-up of
                      26 months, the 3-year OS and bPFS were $84\%$ and $55\%,$
                      respectively. The median time of ADT-free survival was
                      13.5 months. A better clinical outcome was observed for
                      patients receiving concomitant ADT or more than 24 fractions
                      of radiation.PSMA-guided radiotherapy is a promising
                      therapeutic approach with excellent infield control for men
                      with oligorecurrent prostate carcinoma. However,
                      prospective, randomized trials are necessary to determine if
                      this approach confers a survival advantage.},
      cin          = {E030 / C060 / HD01 / E050 / E060},
      ddc          = {610},
      cid          = {I:(DE-He78)E030-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)E050-20160331 /
                      I:(DE-He78)E060-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32405735},
      doi          = {10.1007/s00259-020-04777-z},
      url          = {https://inrepo02.dkfz.de/record/154800},
}